Enanta Pharmaceuticals Inc (NAS:ENTA)
$ 12.465 -0.595 (-4.56%) Market Cap: 264.00 Mil Enterprise Value: 22.76 Mil PE Ratio: 0 PB Ratio: 1.59 GF Score: 70/100

Enanta Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2023 / 06:05PM GMT
Release Date Price: $25.5 (+3.49%)
Brian Abrahams
RBC Capital Markets - Analyst

Let's get started. Hi, again, everyone. I'm Brian Abrahams, one of the senior biotech analysts at RBC Capital Markets. Our next presenting company is Enanta Pharmaceuticals, represented by their President and CEO, Jay Luly, and their SVP of New Product Strategy and Development, Tara Kieffer. Jay and Tara, thanks so much for joining us.

Tara Kieffer
Enanta Pharmaceuticals Inc. - SVP, New Product Strategy and Development

Thanks for inviting us.

Questions & Answers

Brian Abrahams
RBC Capital Markets - Analyst

So just to kick things off, you guys recently presented some data for your asset 235 in COVID, actually just over a week or so ago. Can you maybe just start by walking us through the key findings from that data? What were the most notable signals of efficacy that you observed there?

Jay Luly
Enanta Pharmaceuticals Inc. - President, CEO & Director

So before we begin, I want to remind you, I will be making

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot